NASDAQ$RAPT
RAPT Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
RAPT Therapeutics reported financial results for the second quarter ended June 30, 2024.
RAPT Therapeutics reported a net loss of $27.7 million for the second quarter of 2024, compared to a net loss of $25.3 million for the same period in 2023. Research and development expenses increased to $22.6 million, while general and administrative expenses remained relatively unchanged at $6.7 million.
- Net loss for the second quarter of 2024 was $27.7 million.
- Research and development expenses for the second quarter of 2024 were $22.6 million.
- General and administrative expenses for the second quarter of 2024 were $6.7 million.
- As of June 30, 2024, the Company had cash and cash equivalents and marketable securities of $114.8 million.
Headline financials
Revenue & EPS history
RAPT · Revenue · Quarterly
$0
Forward guidance
The Company estimates that it will incur approximately $0.9 million in restructuring charges in connection with the workforce reduction and expects that the execution of the workforce reduction and the majority of the cash payments related to the restructuring will be substantially completed by the end of the third quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q2 2024
-1.6%
Avg return
Earnings day
-11.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
44%
11 / 25 earnings
Positive
+38.7%
Q3 2022
Best reaction
-45.8%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +2.6% | +4.5% | +21.9% | |
| Q2 2025 | +1.0% | +8.6% | +28.1% | |
| Q1 2025 | +0.0% | -8.3% | +46.2% | |
| Q4 2024 | -0.9% | +0.9% | -6.2% | |
| Q3 2024 | -10.3% | -37.1% | -41.7% | |
| Q2 2024 | -5.8% | +2.5% | -23.3% | |
| Q1 2024 | -45.7% | -50.1% | -51.8% | |
| Q4 2023 | -0.7% | -13.0% | -13.6% | |
| Q3 2023 | +8.2% | — | — | |
| Q2 2023 | -4.8% | — | — | |
| Q1 2023 | -3.5% | — | — | |
| Q4 2022 | -28.4% | — | — | |
| Q3 2022 | +38.7% | — | — | |
| Q2 2022 | +18.7% | — | — | |
| Q1 2022 | +9.7% | — | — | |
| Q4 2021 | +9.2% | — | — | |
| Q3 2021 | -1.9% | — | — | |
| Q2 2021 | -0.4% | — | — | |
| Q1 2021 | -4.0% | — | — | |
| Q4 2020 | +12.0% | — | — | |
| Q3 2020 | -45.8% | — | — | |
| Q2 2020 | +12.3% | — | — | |
| Q1 2020 | +3.7% | — | — | |
| Q4 2019 | +8.7% | — | — | |
| Q3 2019 | -12.3% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro